Unichem Laboratories share news and announcements
NSE: UNICHEMLABBSE: 506690Pharmaceuticals & BiotechnologySmall Cap
Last close ₹472.95down ₹14.80 (3.03%)BSE ₹471.95
Share price at the NSE close on 23 Oct 2026. Previous close ₹487.75.
52-week range of traded prices to 23 Oct 2026
₹278.20Low, 30 Mar 2026₹687.20High, 9 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹3,330 Cr1,036th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 10.9
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹205 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 33.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 May 2026
- 1.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 11.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹205 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 3.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 22 May 2026
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 40,08440.7% delivered
Unichem Laboratories board and management
14 filed, newest first.
Mar 2026
20 Mar · Management
May 2024
Mar 2024
29 Mar · Management
Aug 2023
9 Aug · Management
Sep 2022
Aug 2019
May 2015
Sep 2014
Aug 2012
13 Aug · Management
Mr. Bhagwat S. Dhingra has been appointed as Chief Executive- Domestic Pharma, in place of Mr. Harcharan Singh, with effect from August 06, 2012. He shall report to Dr. Prakash A. Mody, Chairman & Managing Director. Mr. Harcharan Singh will be in an Advisory role for some time and thereafter will be looking for entrepreneurial opportunities.
Apr 2009
8 Apr · Management
Mr. B K Sharma's term of appointment as Whole-time Director has ended on 31st March 2009 and he has expressed his unwillingness to opt for re-appointment. Consequently, he communicated his decision to step down as Director from the Board of Unichem. Mr. Sharma was associated with the Company for nearly 4 decades. The Board has placed its appreciation for his contribution over the years
Mar 2009
30 Mar · Management
Mr. Harcharan Singh has been appointed as Chief Executive - Pharma with effect March 24, 2009. He shall report to the Board of Directors.
Feb 2008
11 Feb · Management
Mr. K Subharaman, has been appointed as Company Secretary of the Company w.e.f. January 18 ,2008
Apr 2007
10 Apr · Management
Mrs. Sanu Kapoor, Manager - Legal & Company Secretary has tendered her resignation with effect from March 23, 2007. Further, Ms. Radhika Kamath, Executive - Legal & Secretarial has been appointed as Compliance officer.